Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan.

Masanori AtsukawaAkihito TsubotaHidenori ToyodaKoichi TakaguchiMakoto NakamutaTsunamasa WatanabeToshifumi TadaAkemi TsutsuiHiroki IkedaHiroshi AbeKeizo KatoHaruki UojimaTadashi IkegamiToru AsanoChisa KondoMai KoedaTomomi OkuboTaeang AraiAi Iwashita-NakagawaNorio ItokawaTakashi KumadaKatsuhiko Iwakiri

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2019)

Community-based, 16-week, ombitasvir/paritaprevir/ritonavir plus ribavirin therapy was highly efficacious and safe in non-cirrhotic patients with HCV genotype 2a infection in a real-world setting.

Keyphrases

hepatitis c virus
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
human immunodeficiency virus
antiretroviral therapy
clinical trial
mesenchymal stem cells
patient reported
smoking cessation